<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029678</url>
  </required_header>
  <id_info>
    <org_study_id>I08011</org_study_id>
    <nct_id>NCT01029678</nct_id>
  </id_info>
  <brief_title>Concomitant Radio-chemotherapy in the Elderly</brief_title>
  <acronym>RACCOSA</acronym>
  <official_title>Phase II Study Evaluating Treatment With Oral Navelbine and Cisplatin Administered Weekly and Concomitant Radiotherapy in Elderly Patients With no Operable NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of non small cell lung cancer (NSCLC)
      treatment with cisplatin and oral vinorelbine administered weekly associated with concomitant
      radiotherapy in elderly patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>during treatment and during the 4 weeks following the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>6 months after the end of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>4 weeks after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin IV</intervention_name>
    <description>Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>66Gy, 33 fractions, 6 week</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 70 years

          -  Independent patients (based on the score of geriatric frailty: IADL = 0, ADL = 0, no
             geriatric syndrome, low comorbidity (comorbidity index of Charlson to 3 or 4),
             depression score 0-1)

          -  Performance Status (ECOG) ≤ 1

          -  Weight loss &lt;10% of usual weight in the last 3 months

          -  Life expectancy greater than 12 weeks

          -  Hematologic function: neutrophils&gt; 1.5 x 10**9 / l, hemoglobin&gt; 9.5 g / dl, platelets
             &gt; 100 x 10**9 / l)

          -  Renal function: creatinine clearance ≥ 50 ml / min calculated by the formula of MDRD

          -  Normal liver function: bilirubin &lt; Limit of Normal (ULN), SGOT and / or SGPT &lt;2.5 x
             UNL

          -  Respiratory Function: FEV ≥ 40% predicted, PaO2 ≥ 60 mm Hg, KCO ≥ 60% predicted

          -  Patient affiliated to a social security regimen or beneficiary of such regimen

          -  Informed consent signed

        The disease

          -  Pathological anatomy: CBP non-small cell (squamous cell carcinoma, adenocarcinoma,
             large cell carcinoma, undifferentiated carcinoma) histologically or cytologically
             proven

          -  Stage IIIAN2 considered inoperable stage IIIB

          -  Presence of at least one measurable target

          -  Delay at least three weeks between surgery and initiation of treatment

          -  No prior treatment with chemotherapy or radiotherapy for lung cancer

        Exclusion Criteria:

          -  Age &lt; 70 years

          -  Performance Status (ECOG) ≥ 2

          -  Hematologic function: neutrophils &lt;1.5 x 10**9 / l, hemoglobin &lt;9.5 g / dl, platelets
             &lt;100 x 10**9 / l)

          -  Renal function: creatinine clearance &lt;50 ml / min calculated by the formula of MDRD

          -  Hepatic: bilirubin&gt; Upper Limit of Normal (ULN), SGOT and / or SGPT&gt; 2.5 x ULN

          -  Respiratory Function: FEV &lt;40% predicted, KCO &lt;60% predicted, PaO2 &lt;60 mmHg

          -  Peripheral neuropathy grade&gt; 1

          -  Unstable cardiac pathology requiring treatment (heart failure, angor of effort,
             arrhythmia) or previous myocardial infarction older than 12 months

          -  Deafness not paired or deafness requiring major achievement of an audiogram-cons may
             indicate taking cisplatin

          -  Neurological or psychiatric disorders prohibiting the understanding of the test

          -  Previous history of cancer except basal cell cancer, carcinoma in situ of the cervix
             treated or any other cancer treated with surgery alone or radiotherapy alone
             extra-thoracic recurrence-free 5 years

          -  Significant malabsorption syndrome or disease affecting the functioning of the
             gastrointestinal tract

        The disease

          -  Pathological anatomy: Bronchioloalveolar carcinoma, neuroendocrine carcinoma, small
             cell carcinoma

          -  Metastatic disease

          -  Pleural drain

          -  Carcinomatous lymphangitis

          -  Operable Cancer

          -  Previously treated for lung cancer disease: radiotherapy, chemotherapy, hormonal
             therapy, endobronchial suctioning older less than eight days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chrystèle LOCHER, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CH Meaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier GAP</name>
      <address>
        <city>GAP</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Pathologie Respiratoire du CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Meaux</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced lung cancer</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

